Apellis Pharmaceuticals announced the FDA approved its product Syfovre, also known as pegcetacoplan injection, for the treatment of geographic atrophy secondary to age-related macular degeneration, according to the press release.
This approval makes Syfovre the first and only treatment for geographic atrophy (GA), the leading cause of blindness in the world. The treatment has a well-demonstrated safety profile following approximately 12,000 injections over 24 months.
As Healio has previously reported, Apellis Pharmaceuticals investigated the efficacy and safety of a pegcetacoplan injection in